Hydrocortisone Therapy for Patients with Septic Shock
Source: View publication →
The CORTICUS trial demonstrated that while low-dose hydrocortisone therapy accelerated the reversal of shock, it did not improve 28-day mortality in patients with septic shock, regardless of their response to a corticotropin stimulation test.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark study challenged the widespread, empirical use of corticosteroids for all patients with septic shock that was adopted following earlier trials. It demonstrated that corticosteroids should not be used as a routine survival-improving intervention, although they may still be considered for refractory hemodynamic support given their effect on shock reversal, while weighing the risk of secondary infections.
Historical Context
The CORTICUS trial was designed to address the uncertainty following the 2002 Annane et al. trial, which had suggested a significant mortality benefit of low-dose hydrocortisone and fludrocortisone in patients with 'relative adrenal insufficiency.' CORTICUS served as a rigorous, multicenter effort to validate these findings and to specifically test the role of the corticotropin stimulation test in guiding steroid administration.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale behind using low-dose hydrocortisone in septic shock, and why was the corticotropin (ACTH) stimulation test initially hypothesized to predict which patients would benefit?
Key Response
Sepsis can lead to 'relative adrenal insufficiency' or Critical Illness-Related Corticosteroid Insufficiency (CIRCI), where the body's cortisol production is inadequate for the level of physiological stress. The ACTH stimulation test was intended to identify 'non-responders' (those with a rise in cortisol <9 mcg/dL) who theoretically have the most blunted adrenal reserve and would thus benefit most from exogenous replacement.
In light of the CORTICUS trial, how should a clinician balance the benefit of faster shock reversal against the risks of secondary complications when deciding to start hydrocortisone in a patient with septic shock?
Key Response
CORTICUS showed that while hydrocortisone significantly shortened the time to shock reversal, it did not improve 28-day mortality and was associated with a higher incidence of superinfections (new episodes of sepsis or septic shock) and hyperglycemia. Therefore, steroids should be reserved for patients who remain hemodynamically unstable despite adequate fluid resuscitation and vasopressor therapy, rather than being used as a routine primary treatment.
Compare and contrast the inclusion criteria and timing of the CORTICUS trial with the earlier 2002 study by Annane et al. How might these differences explain the conflicting mortality outcomes regarding steroid use in septic shock?
Key Response
The Annane trial enrolled patients much earlier (within 6 hours of shock) and focused on a sicker population (higher mortality rate in the placebo group). In contrast, CORTICUS allowed enrollment up to 72 hours after shock onset and included patients with lower severity of illness. The delay in steroid administration and the inclusion of less severe cases in CORTICUS likely diluted any potential mortality benefit that might exist in the hyper-acute phase of refractory shock.
The CORTICUS trial is often cited as the study that 'killed' the ACTH stimulation test in the ICU. How does this shift from a biochemical trigger to a clinical trigger (vasopressor requirement) represent a broader evolution in critical care philosophy?
Key Response
Prior to CORTICUS, management was heavily focused on correcting biochemical 'insufficiency.' CORTICUS demonstrated that the biochemical response to ACTH did not correlate with clinical outcomes. This shifted the paradigm toward using steroids as a 'hemodynamic adjuvant' to reduce vasopressor burden in patients with refractory shock, moving away from the lab-based diagnostic model of CIRCI.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CORTICUS trial was originally powered for 800 patients but stopped at 499 due to slow recruitment. Perform a critical appraisal of how this underpowering affects the interpretation of the 'negative' mortality result, specifically regarding the risk of a Type II error.
Key Response
With only 499 patients, the study was underpowered to detect a mortality difference smaller than the 15% reduction it was originally designed to find. A smaller but clinically relevant benefit (e.g., 5-7%) could have been missed. This highlights the difficulty of achieving definitive 'negative' results in critical care trials when recruitment challenges lead to truncated sample sizes and widened confidence intervals.
As a reviewer, what concerns would you raise regarding the protocol's allowance for hydrocortisone administration up to 72 hours after shock onset, and how does this affect the 'internal validity' of the study's conclusions about mortality?
Key Response
A 72-hour window is exceptionally long for an intervention targeting the acute inflammatory surge of sepsis. By the time many patients were enrolled, their clinical trajectory might have already been determined by other factors, potentially masking the benefit of an intervention that is likely most effective when given early. This 'heterogeneity of timing' is a major threat to the internal validity of a trial testing an anti-inflammatory agent.
How did the CORTICUS trial results directly influence the Surviving Sepsis Campaign (SSC) recommendations regarding the use of corticosteroids and fludrocortisone compared to previous iterations?
Key Response
CORTICUS led the SSC to issue a strong recommendation against using the ACTH stimulation test to identify candidates for steroids. It also contributed to the recommendation to use hydrocortisone alone (without fludrocortisone, unlike the Annane protocol). Current 2021 SSC guidelines suggest IV hydrocortisone at a dose of 200mg/day only if patients require norepinephrine or epinephrine at a dose ≥ 0.25 mcg/kg/min for at least 4 hours, reflecting the CORTICUS finding that benefit is limited to hemodynamic stabilization.
Clinical Landscape
Noteworthy Related Trials
CORTICUS Trial
Tested
Hydrocortisone 50 mg every 6 hours
Population
Patients with septic shock
Comparator
Placebo
Endpoint
Death at 28 days
ADRENAL Trial
Tested
Hydrocortisone 200 mg per day continuous infusion
Population
Patients with septic shock undergoing mechanical ventilation
Comparator
Placebo
Endpoint
90-day mortality
APROCCHSS Trial
Tested
Hydrocortisone 200 mg daily plus fludrocortisone 50 mcg daily
Population
Patients with septic shock
Comparator
Placebo
Endpoint
90-day mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis